GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Net Change in Cash

Revvity (Revvity) Net Change in Cash : $-1,269 Mil (TTM As of Mar. 2024)


View and export this data going back to 1983. Start your Free Trial

What is Revvity Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Revvity's Net Change in Cash for the three months ended in Mar. 2024 was $85 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-1,269 Mil.

Revvity Net Change in Cash Historical Data

The historical data trend for Revvity's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Net Change in Cash Chart

Revvity Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.58 210.72 216.72 -148.59 443.63

Revvity Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,797.81 -935.24 -195.36 -223.59 85.09

Revvity Net Change in Cash Calculation

Revvity's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=91.272+1313.524+-947.121+-14.048
=444

Revvity's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=147.563+-18.181+-35.013+-9.277
=85

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,269 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revvity Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Revvity's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Revvity (Revvity) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Net Change in Cash
Comparable Companies
MEDP CRL NTRA EXAS DGX QGEN LH WAT ILMN RDNT TMO DHR IQV XSWX:LONN IDXX A MTD ICLR SHSE:603259 XPAR:BIM
Traded in Other Exchanges
PKN:Germany PKN:Germany
Address
940 Winter Street, Waltham, MA, USA, 02451
Website
https://www.revvity.com
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Executives
Anita Gonzales officer: Please See Remarks 940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra officer: Please See Remarks 940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg officer: See Remarks 940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121